Annual Report of Testing Methods

Annual Assessment

Annually, each funded laboratory is required to report to CDC a summary of its testing methods. These summary reports have to be submitted by email communication to <u>ARLN_DHQP@cdc.gov</u> at the beginning of each calendar year.

	Method(s)
Organism identification	
[e.g., MALDI, VITEK, API20E, Biochemical,	
Other (specify)]	
Antimicrobial susceptibility testing (AST)	
[e.g., Etest, Broth Microdilution, Disk	
Diffusion, Digital Dispenser; Other (specify)]	
Carbapenemase production testing	
[e.g., CarbaNP; mCIM; Other (specify)]	
Carbapenemase gene identification	
[e.g., Cepheid Gene Xpert; CDC PCR, Streck ARM-D; Nanosphere Verigene; In- House	
PCR; or other (specify)]	
	Gene Targets Detected
Carbapenemase genes targets	
[e.g., KPC, NDM, OXA-23, OXA-48, VIM,	
IMP-1 group, Expanded IMP variants (CDC	
assay)]	
Other gene targets	
[e.g., mcr 1, mcr 2, Other (specify)]	
	Whole genome sequencing capacities
Number of MiSeq, HiSeq, NextSeq, or other	
sequencing platforms	
PacBio capacity	
DNA extraction method(s)	
Description of fragment analyzers, tape	
stations, bioanalyzers, library prep kits, and QC	
equipment	
Bioinformatics capacities and/or staff	
1	

Public reporting burden of this collection of information is estimated to average 6 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB Control Number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA 0920-1310